ReviewSeminars in immunopathology2016
Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
Review in Seminars in immunopathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04179292 (The Effect of Physiotherapy Program in Scleroderma Patients), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Physiotherapy Program in Scleroderma Patients: A Randomized Clinical Trial
Who cites it
38 citing papers in PubMed.
- Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease.Scientific reports · 2020Trial
- The Role of Solute Carriers in the Metabolic Reprogramming of Skin Diseases.Clinical reviews in allergy & immunology · 2025Review
- Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases.Immunity, inflammation and disease · 2025Review
- Parvovirus B19 in Rheumatic Diseases.Microorganisms · 2024Review
- Erasmus syndrome: case description of a rare entity.Quantitative imaging in medicine and surgery · 2024Article
- Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database.Drugs - real world outcomes · 2024Article
- Article
- αvβ3 Integrin as a Link between the Development of Fibrosis and Thyroid Hormones in Systemic Sclerosis.International journal of molecular sciences · 2023Article
- Loss of Protein Kinase D2 Activity Protects Against Bleomycin-Induced Dermal Fibrosis in Mice.Laboratory investigation; a journal of technical methods and pathology · 2023Article
- Fat transplantation induces dermal adipose regeneration and reverses skin fibrosis through dedifferentiation and redifferentiation of adipocytes.Stem cell research & therapy · 2022Article
- Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis.Stem cell research & therapy · 2022Article
- Abnormal expression of interleukin-6 is associated with epidermal alternations in localized scleroderma.Clinical rheumatology · 2022Article
- Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.Clinical reviews in allergy & immunology · 2022Review
- Dental implants in patients suffering from systemic sclerosis: a retrospective analysis of clinical outcomes in a case series with 24 patients.International journal of implant dentistry · 2021Article
- The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo.Biomedicines · 2021Article
- Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience.Wiener klinische Wochenschrift · 2021Observational
- Systemic sclerosis manifesting as intractable gastro-oesophageal reflux and diarrhoea: a case report from Kenya.The Pan African medical journal · 2021Article
- The Effects of Tofacitinib-Mediated Janus Kinase/Signal Transducers and Activators of the Transcription Signal Pathway Inhibition on Collagen Biosynthesis in Hepatic and Skin Fibroblast Cell Culture.Archives of rheumatology · 2020Article
- Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis.Arthritis research & therapy · 2020Article
- The Role of IL-6 in Skin Fibrosis and Cutaneous Wound Healing.Biomedicines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Skin and organ fibrosis are key manifestations of SSc, for which no generally accepted therapy is available. Thus, there is a high unmet need for novel anti-fibrotic therapeutic strategies in SSc. At the same time, important progress has been made in the identification and characterization of potential molecular targets in fibrotic diseases over the recent years. In this review, we have selected four targeted therapies, which are tested in clinical trials in SSc, for in depths discussion of their preclinical characterization. Soluble guanylate cyclase (sGC) stimulators such as riociguat might target both vascular remodeling and tissue fibrosis. Blockade of interleukin-6 might be particularly promising for early inflammatory stages of SSc. Inhibition of serotonin receptor 2b signaling links platelet activation to tissue fibrosis. Targeting simultaneously multiple key molecules with the multityrosine kinase-inhibitor nintedanib might be a promising approach in complex fibrotic diseases such as SSc, in which many partially independent pathways are activated. Herein, we also give a state of the art overview of the current classification, clinical presentation, diagnostic approach, and treatment options of localized scleroderma. Finally, we discuss whether the novel targeted therapies currently tested in SSc could be used for localized scleroderma.
Indexed as
Identifiers
26577237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.